PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy

BACKGROUND: The rapid development of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has generated an urgent need for biomarkers assisting the selection of patients eligible for therapy. The use of PD-L1 immunohistochemistry, which has been suggested as a predictive biomarker,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gevensleben, Heidrun, Holmes, Emily Eva, Goltz, Diane, Dietrich, Jörn, Sailer, Verena, Ellinger, Jörg, Dietrich, Dimo, Kristiansen, Glen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346762/
https://www.ncbi.nlm.nih.gov/pubmed/27835597
http://dx.doi.org/10.18632/oncotarget.13161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346762/
https://www.ncbi.nlm.nih.gov/pubmed/27835597
http://dx.doi.org/10.18632/oncotarget.13161

Ejemplares similares